

# Immunopharmacology of non-digestible carbohydrates: a breakthrough for clinical nutrition?

Prof. Dr. Johan Garssen

**Zurich**  
**March 20<sup>th</sup> 2009**





Bringing Science to Life

**60 - 70% of the current drugs have  
their origin in edible plants, fruits,  
vegetables, herbals or ferments**


***"Let medicine be thy food,  
and food be thy medicine."***

Hippocrates of Cos, Greece  
460-377 B.C.





## Overlap between Nutrition and Pharma




# Health claims/Immune claims/Reimbursement


- What do we need?
  - Reliable and high quality science
  - Regulation/Guidelines (FDA / medical food/ EFSA / FSMP)
  - Laws and inspection




## Translational Research – WHO / ILSI / FDA / TIP



## Organs




## Cells



**60 – 70 % of immune cells in the gastro- intestinal tract !!**



# Immune system





# Immune system



Hyper immune- responsiveness:

Allergy

Autoimmunity

Chronic inflammatory diseases




Hypo immune- responsiveness:

Infections

Tumors/metastasis



# Immune regulation





# Immune regulation



## Cellular immunity:


Th1:	IL-2, IL-3, IL-12, IFN- $\gamma$ , IL-7, IL-15, IL-23
Th2:	IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13
Tr/Th3:	IL-10, TGF- $\beta$ 1 (inhibitory cytokines)

## Humoral Immunity:

Th1:	IgG1, IgG3
Th2:	IgG2, IgE
Tr/Th3:	IgG4



# Immune regulation in the intestine: a bridge to systemic immunity



## Immune disorders

- HIV
- COPD
- Allergies
- Asthma
- Atopic eczema
- Coeliac disease
- Cystic Fibroses
- Cancer
- Elderly
- Infants

Th1 ↓, Th2 ↑, Th1/Th2 ↓

Th1 ↑

Th2 ↑ (type I allergy)

Th2 ↑

Th2 ↑

Th1 ↑

Th1 ↑?


Th1 ↓

Th1 ↓

Th1 ↓, Th2 ↑



## Th1 and Th2 activity as a function of age





## Compounds with immunological properties in human milk

### Anti-microbial compounds

Immunoglobulins: sIgA, SIgG, SIgM  
Lactoferrin, lactoferrin B and H  
Lysozyme  
Lactoperoxidase  
Nucleotide-hydrolyzing  
Antibodies  
κ-casein and α-lactalbumin  
Haptocorrin  
Mucins  
Lactadherin  
Free secretory component  
Oligosaccharides and pre-biotics  
Fatty acids  
Maternal leukocytes and Cytokines  
sCD14  
Complement and complement receptors  
β-defensin-1  
Toll-like receptors  
Bifidus factor  
Tolerance/priming compounds  
Cytokines: IL10 and TGFβ  
Anti-idiotypic antibodies

### Immune development compounds


Macrophages  
Neutrophils  
Lymphocytes  
Cytokines  
Growth factors  
Hormones  
Milk peptides  
Long-chain polyunsaturated fatty acids  
Nucleotides  
Adhesion molecules

### Anti-inflammatory compounds


Cytokines: IL-10 and TGFβ  
IL-1 receptor antagonist  
TNFα and IL-6 receptors  
sCD14  
Adhesion molecules  
Long-chain polyunsaturated fatty acids  
Hormones and growth factors  
Osteoprotegerin  
Long-chain polyunsaturated fatty acids  
Hormones and growth factors



### Oligosaccharides



## Translational research – WHO/ILSI/FDA/TIP






**scGOS e.g. DP3**

**Gal( $\beta$ 1-4)Gal( $\beta$ 1-4)Glc**



**lcFOS e.g. DP10**

**[Frc( $\beta$ 2-1)]<sub>8</sub>Frc( $\beta$ 2-1)Glc**




**90 % GOS: short-chain  $\beta$ -Galacto-OligoSaccharides from lactose**

**10 % FOS: long-chain  $\beta$ -Fructo-OligoSaccharides from chicory**





# Improvement gut barrier? – First line defense








# Oligosaccharides

*SCFA differentially stimulate mucin production: mono and co-cultures*






## scGOS/lcFOS stimulates TLR9 induced IFN- $\gamma$ production by human blood cells in co-culture systems with human gut epithelial cells




# IcFOS stimulates $\text{NO}_2^-$ production by murine MØ



# Vaccination model



## Study parameters:

- DTH
- Influenza specific antibody titers
- Ex-vivo lymphocyte restimulation





## GOS/lcFOS improves vaccination



## Conclusions so far

- ✓ GOS/lcFOS can affect systemic immunity (Th1/Th2)
  - ✓ Regular T cells play a crucial role
  - ✓ There is synergy between different types of oligosaccharides
  - ✓ Not all oligosaccharides affect the immune system
- 
- What about improved resistance to infections
  - What about reduced risk for IgE mediated allergy



## Immune disorders

- HIV
- COPD
- Allergies
- Asthma
- Atopic eczema
- Coeliac disease
- Cystic Fibroses
- Cancer
- Elderly
- Infants

Th1 ↓, Th2 ↑, Th1/Th2 ↓

Th1 ↑

Th2 ↑ (type I allergy)

Th2 ↑

Th2 ↑

Th1 ↑

Th1 ↑?


Th1 ↓

Th1 ↓




Th1 ↓, Th2 ↑



# Immune skewing






## scGOS/lcFOS affects Th1/Th2 via DC/T-cell interaction





**Stimulation of anti-allergic profile**

## Allergy (respiratory)




### GOS/lcFOS impairs allergic inflammation in the lungs






# Allergy (respiratory)



**GOS/lcFOS impairs IgE in serum**



## Immune disorders

■	HIV
■	COPD
■	Allergies
■	Asthma
■	Atopic eczema
■	Coeliac disease
■	Cystic Fibroses
■	Cancer
■	Elderly
■	Infants

Th1 ↓, Th2 ↑, Th1/Th2 ↓

Th1 ↑

Th2 ↑ (type I allergy)

Th2 ↑

Th2 ↑

Th1 ↑



Th1 ↑?


Th1 ↓

Th1 ↓



Th1 ↓, Th2 ↑

## *Cytomegalovirus* infection model in mice (systemic infection)






# Oligosaccharides decrease MCMV load *in vivo*






## Translational research – WHO/ILSI/FDA/TIP





## Atopic Dermatitis in high-risk infants at 6 months






## GOS/lcFOS decrease serum IgE in high-risk infants at 6 months



## Early dietary intervention with a mixture of prebiotic oligosaccharides reduce the incidence of infections during the first 2 years of life

	Placebo	scGOS/lcFOS
	<i>episode/infant</i>	
<i>n</i>	68	66
Physician-diagnosed infections		
Overall (any kind of infection)**	5.9 ± 4.1	4.1 ± 3.1
URTI <sup>†</sup>	3.2 ± 2.2	2.1 ± 1.8
Lower respiratory tract infections	1.3 ± 0.8	0.9 ± 1.1
Otitis media	0.7 ± 1.2	0.5 ± 1.0
Gastrointestinal infections	0.6 ± 0.9	0.4 ± 0.7
Urinary tract infections	0.1 ± 0.5	0.0 ± 0.0
Infections requiring antibiotic prescriptions*	2.7 ± 2.4	1.8 ± 2.3
Fever episodes recorded by parents <sup>‡</sup>	3.9 ± 2.5	2.2 ± 1.9

<sup>1</sup> Values are means ± SD. \*Different from placebo,  $P < 0.05$ , \*\* $P = 0.01$ , <sup>†</sup> $P < 0.01$ , <sup>‡</sup> $P < 0.0001$ .



# Early dietary intervention with a mixture of prebiotic oligosaccharides reduce the incidence of acute diarrhoea and protect from recurrent URTI

Table.2 Primary outcomes (intention to treat analysis)

	GOS/FOS group	Formula Standard group	P value
<b>Gastrointestinal infections</b>			
Number of episodes of diarrhea	22	44	.02
Number of children with 1 episode of diarrhea	19/169	37/173	.0129
<b>Upper respiratory tract infections</b>			
Number of episodes of URTI	241	302	NS
Number of children with at least 1 URTI	84/169	87/173	NS
Number of children with > 3 URTI	22/169	36/173	.06
<b>Use of antibiotics for URTI</b>			
Number of antibiotic courses/URTI	123/241	190/302	NS
Number of children with at least 1 antibiotic course	65/84	78/87	.038
Number of children with ≥2 antibiotic courses	32/84	59/87	.0001
Number of children with ≥3 antibiotic courses	14/84	34/87	.0012

## Immune disorders

- HIV
- COPD
- Allergies
- Asthma
- Atopic eczema
- Coeliac disease
- Cystic Fibroses
- **Cancer**
- Elderly
- Infants

**Th1 ↓, Th2 ↑, Th1/Th2 ↓**

**Th1 ↑**

**Th2 ↑ (type I allergy)**

**Th2 ↑**

**Th2 ↑**

**Th1 ↑**

**Th1 ↑?**


**Th1 ↓**

**Th1 ↓**

**Th1 ↓, Th2 ↑**




# Summary



*From invited review on oligosaccharides: critical reviews immunology: Paul Vos et al., 2007*

## Conclusion (1)


- 60 - 70% of the immune cells are present in the gastro-intestinal tract
- There is a crucial interaction between gut associated and systemic immunity
- Non-digestible carbohydrates can affect the immune system both locally as well as systemically (less infections, less allergic inflammation) > a new chapter in immuno-pharmacology





## Conclusion (2)

- Non-digestible carbohydrates are a promising tool to improve immune responsiveness in immuno-compromised individuals (cancer, HIV, elderly,..)
- Food immunology is one of the most promising new life sciences at the interface between food and pharma
- Translational bi-directional research is essential





***“There is a reason behind everything in nature.”***



***Aristoteles***